NCT07129148Recruiting
Mobile Health and Wearable Devices for Diabetes Complication Management
Study on the Applicability of New Technologies for Diabetes Complication Management Based on Mobile Health and Wearable Devices
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
The value of intelligent lifestyle intervention for T2D and its complications has been initially explored, but evidence-based support for the effectiveness of related AI risk prediction models and intervention models remains to be confirmed. The primary objective of this study is to verify the effectiveness of an AI model for predicting the risk of T2D complications based on phenotype, laboratory indicators and wearable device indicators, and to explore the effect and applicability of an intelligent lifestyle intervention model combining wearable devices and smartphones in preventing T2D complications.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 6000 (estimated)
- First submitted
- 6 Aug 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Oct 2026
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Diseases
- Type 2 diabetes
- NCT number
- NCT07129148
What you commit to
- Study type: Interventional
- Planned participants: 6000
- From 1 Oct 2025 to the primary completion date, 1 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcoholism or drug addiction;
- Receiving insulin therapy;
Other illness
- Having severe mental illness or language barriers;
- Suffering from malignant tumors;
- Suspected active infections (such as active pulmonary tuberculosis, pneumonia, etc.);
- A history of definite major adverse cardiovascular events and/or revascularization and/or intravenous thrombolysis and/or endovascular thrombectomy;
- Uncontrolled hyperthyroidism or hypothyroidism, pituitary-adrenal dysfunction, or other endocrine diseases;
Lab values
- Severe hepatic and renal insufficiency (alanine transaminase and/or aspartate transaminase \> 3 times the upper limit of normal; estimated glomerular filtration rate \< 15 mL/min/1.73 m²);
Other
- Pregnant or lactating women;
- Unable to accept new comprehensive intervention technologies for various reasons (such as personal beliefs, economic factors, etc.).
Who the study is looking for
- Confirmed diagnosis of Type 2 Diabetes;
- Aged ≥ 18 years;
- Able to accept the diabetes management model with AI-assisted management and wearable device monitoring;
- Able to provide complete lifestyle records, including medical history, medication status, diet, exercise, etc.;
- Fully understand the purpose, nature, and methods of the study, voluntarily participate in this study, accept a 3-month follow-up, and sign the informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Second Xiangya Hospital of Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.